Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection

South Valley University

Status: Completed

Conditions: Covid19

Treatments: Drug: Placebo; Drug: Azithromycin; Drug: Clarithromycin 500mg

Study type: Interventional

Funder types: Other

Identifiers

NCT04622891

SVU-MED-CHT019-420860

Details and patient eligibility

About

The current study was conducted at Qena Governorate, Egypt, during the period from May 2020, to July 2020. The study included 305 COVID-19 cases diagnosed by PCR, patients were randomly assigned to one of three study limps, Azithromycin 500 mg/24 h for 7 days, Clarithromycin 500 /12 h for 7 days, or a control group with no antibiotics, All three groups received only symptomatic treatment for control of fever and cough

Full description

The current study was conducted at Qena Governorate, Egypt, during the period from May 2020, to July 2020. The study included 305 COVID-19 cases diagnosed by PCR, patients were randomly assigned to one of three study limps, Azithromycin 500 mg/24 h for 7 days, Clarithromycin 500 /12 h for 7 days, or a control group with no antibiotics, All three groups received only symptomatic treatment for control of fever and cough.

All study participants underwent full clinical evaluation including duration of fever, cough, dyspnea, anosmia or GIT symptoms, C-reactive protein (CRP), serum ferritin, D-dimer, Complete blood count (CBC), non-contrast chest computed tomography (CT) which was repeated 2 weeks after the start of treatment.

The Azithromycin group included, 107 patients, mean age 45.8 ±18 years, 73 male and 34 female, the Clarithromycin group included 99 patients mean age 46.1±19 years, 68 males and 31 female, the control group included 99 patients, with mean age 41.1 ± 18 years, 73 male and 28 female.

Enrollment: 300 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• COVID-19 cases
• Oxygen saturation > 93%
• Age >18 years

Exclusion criteria

• Patients <18 years,
• patients with Oxygen saturation < 93%, patients with
• Diabetes mellitus or
• heart failure,
• patients on chemotherapy or immunosuppressive therapy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

300 participants in 3 patient groups, including a placebo group

clarithromycin

Experimental group

Description:

clarithromycin group

Treatment:

Drug: Clarithromycin 500mg

Azithromycin

Active Comparator group

Description:

azithromycin group

Treatment:

Drug: Azithromycin

control

Placebo Comparator group

Description:

control group

Treatment:

Drug: Placebo